ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 810,51
0,51%
Dow Jones
44 025,81
1,24%
DAX
21 245,07
0,97%
Brent Oil
78,90
0,19%
Bitcoin
104 993,95
-1,11%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) Actualités

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IONS
DateHeureSourceTitreSymboleSociété
18/01/202501h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
17/01/202501h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
13/01/202514h00PR Newswire (US)Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentumNASDAQ:IONSIonis Pharmaceuticals Inc
08/01/202522h11PR Newswire (US)Ionis to present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IONSIonis Pharmaceuticals Inc
20/12/202420h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
20/12/202400h28PR Newswire (US)TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietNASDAQ:IONSIonis Pharmaceuticals Inc
15/11/202402h34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
13/11/202414h55Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
08/11/202416h52Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IONSIonis Pharmaceuticals Inc
07/11/202413h05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
06/11/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IONSIonis Pharmaceuticals Inc
06/11/202413h01PR Newswire (US)Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman SyndromeNASDAQ:IONSIonis Pharmaceuticals Inc
06/11/202413h00PR Newswire (US)Ionis reports third quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
04/11/202415h44PR Newswire (US)Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAENASDAQ:IONSIonis Pharmaceuticals Inc
23/10/202413h05PR Newswire (US)Ionis to hold third quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
21/10/202408h08PR Newswire (US)WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosisNASDAQ:IONSIonis Pharmaceuticals Inc
08/10/202413h30GlobeNewswire Inc.New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMANASDAQ:IONSIonis Pharmaceuticals Inc
03/10/202413h00PR Newswire (US)New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingNASDAQ:IONSIonis Pharmaceuticals Inc
02/10/202400h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
01/10/202413h00PR Newswire (US)Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander diseaseNASDAQ:IONSIonis Pharmaceuticals Inc
10/09/202423h19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IONSIonis Pharmaceuticals Inc
10/09/202403h10PR Newswire (US)Ionis announces pricing of $500.3 million public offeringNASDAQ:IONSIonis Pharmaceuticals Inc
09/09/202422h20PR Newswire (US)Ionis announces proposed public offering of common stockNASDAQ:IONSIonis Pharmaceuticals Inc
05/09/202403h33Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
04/09/202413h30GlobeNewswire Inc.Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMANASDAQ:IONSIonis Pharmaceuticals Inc
05/08/202421h35Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IONSIonis Pharmaceuticals Inc
01/08/202413h00PR Newswire (US)Ionis reports second quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
31/07/202415h00PR Newswire (US)Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersenNASDAQ:IONSIonis Pharmaceuticals Inc
22/07/202413h00PR Newswire (US)Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
19/07/202414h24PR Newswire (US)Ionis to hold second quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS

Dernières Valeurs Consultées

BIT
UC6M06
Unicredit Bank
LSE
MMC
Management Consulting
NASDAQ
VUSXX
Vanguard Admiral Fund Treasury M
BIT
UC610F
Unicredit Bank
LSE
0QE5
Tele2 Ab
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés